AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. VERV
  4. [Form 4] Verve Therapeutics, Inc. Insider Trading Activity

[Form 4] Verve Therapeutics, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Key take-aways from Verve Therapeutics (VERV) Form 4

On 25 Jul 2025, CFO Allison Dorval reported the disposition of all remaining Verve equity as a result of Eli Lilly鈥檚 previously announced acquisition. Transactions coded 鈥淯鈥� confirm automatic treatment under the 16 Jun 2025 merger agreement:

  • 13,280 common shares tendered for $10.50 cash plus one CVR per share; post-transaction share balance: 0.
  • Cash-out of 513,000 stock options (exercise prices $6.01鈥�$12.75) and 80,625 RSUs; all derivative positions now zero.

The filing notes the conversion mechanics: cash equal to the spread (where applicable) and issuance of a non-tradable CVR worth up to $3.00, contingent on a milestone. Completion of the tender offer and subsequent merger on 25 Jul 2025 leaves Verve as a wholly owned Lilly subsidiary; the reporting person is no longer a VERV insider.

Punti chiave dal Formulario 4 di Verve Therapeutics (VERV)

Il 25 luglio 2025, la CFO Allison Dorval ha comunicato la cessione di tutte le azioni residue di Verve a seguito dell'acquisizione precedentemente annunciata da Eli Lilly. Le transazioni contrassegnate con il codice 鈥淯鈥� confermano il trattamento automatico secondo l'accordo di fusione del 16 giugno 2025:

  • 13.280 azioni ordinarie consegnate in cambio di 10,50 $ in contanti pi霉 un CVR per azione; saldo azionario post-transazione: 0.
  • Liquidazione di 513.000 opzioni su azioni (prezzi di esercizio da 6,01 $ a 12,75 $) e 80.625 RSU; tutte le posizioni derivate ora azzerate.

Il documento descrive la meccanica della conversione: pagamento in contanti pari allo spread (se applicabile) e emissione di un CVR non negoziabile del valore massimo di 3,00 $, condizionato al raggiungimento di un traguardo. Il completamento dell'offerta pubblica di acquisto e della successiva fusione il 25 luglio 2025 rende Verve una controllata interamente posseduta da Lilly; la persona che ha effettuato la comunicazione non 猫 pi霉 un insider di VERV.

Puntos clave del Formulario 4 de Verve Therapeutics (VERV)

El 25 de julio de 2025, la CFO Allison Dorval report贸 la disposici贸n de todas las acciones restantes de Verve como resultado de la adquisici贸n previamente anunciada por Eli Lilly. Las transacciones codificadas como 鈥淯鈥� confirman el tratamiento autom谩tico seg煤n el acuerdo de fusi贸n del 16 de junio de 2025:

  • 13,280 acciones comunes entregadas por $10.50 en efectivo m谩s un CVR por acci贸n; saldo de acciones despu茅s de la transacci贸n: 0.
  • Pago en efectivo de 513,000 opciones sobre acciones (precios de ejercicio entre $6.01 y $12.75) y 80,625 RSU; todas las posiciones derivadas ahora en cero.

El informe detalla la mec谩nica de conversi贸n: efectivo igual al diferencial (cuando corresponde) y emisi贸n de un CVR no negociable valorado hasta en $3.00, condicionado a un hito. La finalizaci贸n de la oferta p煤blica de adquisici贸n y la fusi贸n posterior el 25 de julio de 2025 convierte a Verve en una subsidiaria totalmente propiedad de Lilly; la persona que reporta ya no es un insider de VERV.

Verve Therapeutics (VERV) Form 4 欤检殧 雮挫毄

2025雲� 7鞗� 25鞚�, CFO Allison Dorval鞚� Eli Lilly臧� 鞚挫爠鞐� 氚滍憸頃� 鞚胳垬搿� 鞚疙暣 雮晞鞛堧姅 氇摖 Verve 欤检嫕鞚� 觳橂秳頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 鈥淯鈥� 旖旊摐臧� 攵欖潃 瓯半灅電� 2025雲� 6鞗� 16鞚� 頃╇硲 瓿勳暯鞐� 霐半ジ 鞛愲彊 觳橂Μ毳� 頇曥澑頃╇媹雼�:

  • 13,280 氤错喌欤�臧� 欤茧嫻 順勱笀 10.50雼煬鞕� 1 CVR搿� 鞝滌稖霅橃棃鞙茧┌, 瓯半灅 頉� 欤检嫕 鞛旉碃電� 0鞛呺媹雼�.
  • 頄夓偓臧� 6.01~12.75雼煬鞚� 513,000 鞀ろ啞鞓奠厴瓿� 80,625 RSU 順勱笀頇�; 氇摖 韺岇儩 韽靺橃潃 鞚挫牅 0鞛呺媹雼�.

鞁犼碃靹滌棎電� 鞝勴櫂 氚╈嫕鞚� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟: 頃措嫻霅橂姅 瓴届毎 鞀ろ攧霠堧摐鞐� 頃措嫻頃橂姅 順勱笀 歆�旮夑臣 斓滊寑 3.00雼煬 臧�旃橃潣 牍勱卑霝� 臧�電� CVR 氚滍枆, 鞚措姅 韸轨爼 鞚挫爼響� 雼劚鞐� 霐半澕 雼澕歆戨媹雼�. 2025雲� 7鞗� 25鞚� 瓿店皽 毵れ垬 氚� 鞚错泟 頃╇硲 鞕勲搿� Verve電� Lilly鞚� 鞕勳爠 鞛愴殞靷 鞝勴櫂霅橂┌, 鞁犼碃鞛愲姅 雿� 鞚挫儊 VERV 雮措秬鞛愱皜 鞎勲嫏雼堧嫟.

Points cl茅s du Formulaire 4 de Verve Therapeutics (VERV)

Le 25 juillet 2025, la CFO Allison Dorval a d茅clar茅 la cession de toutes les actions restantes de Verve suite 脿 l'acquisition annonc茅e pr茅c茅demment par Eli Lilly. Les transactions cod茅es 芦 U 禄 confirment le traitement automatique selon l'accord de fusion du 16 juin 2025 :

  • 13 280 actions ordinaires remises contre 10,50 $ en esp猫ces plus un CVR par action ; solde d'actions apr猫s transaction : 0.
  • Rachat en esp猫ces de 513 000 options d'achat d'actions (prix d'exercice de 6,01 $ 脿 12,75 $) et 80 625 RSU ; toutes les positions d茅riv茅es sont d茅sormais nulles.

Le d茅p么t pr茅cise les modalit茅s de conversion : paiement en esp猫ces 茅gal 脿 l'茅cart (le cas 茅ch茅ant) et 茅mission d'un CVR non n茅gociable d'une valeur maximale de 3,00 $, conditionn茅 脿 la r茅alisation d'un jalon. La finalisation de l'offre publique d'achat et de la fusion ult茅rieure le 25 juillet 2025 fait de Verve une filiale en propri茅t茅 exclusive de Lilly ; la personne d茅clarant n'est plus un initi茅 de VERV.

Wichtige Erkenntnisse aus dem Form 4 von Verve Therapeutics (VERV)

Am 25. Juli 2025 meldete CFO Allison Dorval die Ver盲u脽erung aller verbleibenden Verve-Aktien infolge der zuvor angek眉ndigten 脺bernahme durch Eli Lilly. Transaktionen mit dem Code 鈥濽鈥� best盲tigen die automatische Abwicklung gem盲脽 dem Fusionsvertrag vom 16. Juni 2025:

  • 13.280 Stammaktien wurden f眉r 10,50 USD in bar plus eine CVR pro Aktie eingereicht; Aktienbestand nach der Transaktion: 0.
  • Auszahlung von 513.000 Aktienoptionen (Aus眉bungspreise 6,01鈥�12,75 USD) und 80.625 RSUs; alle derivativen Positionen sind jetzt auf null.

Die Einreichung erl盲utert die Umwandlungsmodalit盲ten: Barausgleich in H枚he der Differenz (sofern zutreffend) und Ausgabe eines nicht handelbaren CVR im Wert von bis zu 3,00 USD, abh盲ngig von einem Meilenstein. Der Abschluss des 脺bernahmeangebots und der anschlie脽enden Fusion am 25. Juli 2025 macht Verve zu einer hundertprozentigen Tochtergesellschaft von Lilly; die meldende Person ist kein Insider von VERV mehr.

Positive
  • Merger completion confirmed, removing transaction uncertainty for former VERV shareholders.
  • Cash-and-CVR consideration has been delivered to insider, evidencing operational execution of deal terms.
Negative
  • No remaining insider ownership, eliminating traditional governance oversight from legacy management.
  • Future value hinges on CVR milestone, which carries timing and probability risk.

Insights

TL;DR: Filing verifies Lilly鈥揤erve deal closure; insider equity fully settled, eliminating completion risk for arbitrage investors.

The automatic cancellation of all common, option and RSU holdings underlines that the cash-and-CVR structure is now effective. With no residual equity outstanding, completion risk is effectively zero and any remaining spread in VERV trading should converge to cash consideration. The CVR retains upside optionality tied to a single milestone and is unregistered, thus illiquid. Overall, the update is procedurally positive, but adds little incremental value beyond confirming the 25 Jul closing.

TL;DR: Routine insider disposition; material value already priced, limited actionable insight for new investors.

The Form 4 is largely administrative, detailing how the CFO鈥檚 13,280 shares and 593,625 equity awards were converted to cash/CVR. It reaffirms zero stand-alone VERV float going forward. Investors now focus solely on the CVR鈥檚 milestone probability; no additional financials are provided. Impact on existing portfolios is neutral unless one is modelling CVR pay-outs.

Punti chiave dal Formulario 4 di Verve Therapeutics (VERV)

Il 25 luglio 2025, la CFO Allison Dorval ha comunicato la cessione di tutte le azioni residue di Verve a seguito dell'acquisizione precedentemente annunciata da Eli Lilly. Le transazioni contrassegnate con il codice 鈥淯鈥� confermano il trattamento automatico secondo l'accordo di fusione del 16 giugno 2025:

  • 13.280 azioni ordinarie consegnate in cambio di 10,50 $ in contanti pi霉 un CVR per azione; saldo azionario post-transazione: 0.
  • Liquidazione di 513.000 opzioni su azioni (prezzi di esercizio da 6,01 $ a 12,75 $) e 80.625 RSU; tutte le posizioni derivate ora azzerate.

Il documento descrive la meccanica della conversione: pagamento in contanti pari allo spread (se applicabile) e emissione di un CVR non negoziabile del valore massimo di 3,00 $, condizionato al raggiungimento di un traguardo. Il completamento dell'offerta pubblica di acquisto e della successiva fusione il 25 luglio 2025 rende Verve una controllata interamente posseduta da Lilly; la persona che ha effettuato la comunicazione non 猫 pi霉 un insider di VERV.

Puntos clave del Formulario 4 de Verve Therapeutics (VERV)

El 25 de julio de 2025, la CFO Allison Dorval report贸 la disposici贸n de todas las acciones restantes de Verve como resultado de la adquisici贸n previamente anunciada por Eli Lilly. Las transacciones codificadas como 鈥淯鈥� confirman el tratamiento autom谩tico seg煤n el acuerdo de fusi贸n del 16 de junio de 2025:

  • 13,280 acciones comunes entregadas por $10.50 en efectivo m谩s un CVR por acci贸n; saldo de acciones despu茅s de la transacci贸n: 0.
  • Pago en efectivo de 513,000 opciones sobre acciones (precios de ejercicio entre $6.01 y $12.75) y 80,625 RSU; todas las posiciones derivadas ahora en cero.

El informe detalla la mec谩nica de conversi贸n: efectivo igual al diferencial (cuando corresponde) y emisi贸n de un CVR no negociable valorado hasta en $3.00, condicionado a un hito. La finalizaci贸n de la oferta p煤blica de adquisici贸n y la fusi贸n posterior el 25 de julio de 2025 convierte a Verve en una subsidiaria totalmente propiedad de Lilly; la persona que reporta ya no es un insider de VERV.

Verve Therapeutics (VERV) Form 4 欤检殧 雮挫毄

2025雲� 7鞗� 25鞚�, CFO Allison Dorval鞚� Eli Lilly臧� 鞚挫爠鞐� 氚滍憸頃� 鞚胳垬搿� 鞚疙暣 雮晞鞛堧姅 氇摖 Verve 欤检嫕鞚� 觳橂秳頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 鈥淯鈥� 旖旊摐臧� 攵欖潃 瓯半灅電� 2025雲� 6鞗� 16鞚� 頃╇硲 瓿勳暯鞐� 霐半ジ 鞛愲彊 觳橂Μ毳� 頇曥澑頃╇媹雼�:

  • 13,280 氤错喌欤�臧� 欤茧嫻 順勱笀 10.50雼煬鞕� 1 CVR搿� 鞝滌稖霅橃棃鞙茧┌, 瓯半灅 頉� 欤检嫕 鞛旉碃電� 0鞛呺媹雼�.
  • 頄夓偓臧� 6.01~12.75雼煬鞚� 513,000 鞀ろ啞鞓奠厴瓿� 80,625 RSU 順勱笀頇�; 氇摖 韺岇儩 韽靺橃潃 鞚挫牅 0鞛呺媹雼�.

鞁犼碃靹滌棎電� 鞝勴櫂 氚╈嫕鞚� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟: 頃措嫻霅橂姅 瓴届毎 鞀ろ攧霠堧摐鞐� 頃措嫻頃橂姅 順勱笀 歆�旮夑臣 斓滊寑 3.00雼煬 臧�旃橃潣 牍勱卑霝� 臧�電� CVR 氚滍枆, 鞚措姅 韸轨爼 鞚挫爼響� 雼劚鞐� 霐半澕 雼澕歆戨媹雼�. 2025雲� 7鞗� 25鞚� 瓿店皽 毵れ垬 氚� 鞚错泟 頃╇硲 鞕勲搿� Verve電� Lilly鞚� 鞕勳爠 鞛愴殞靷 鞝勴櫂霅橂┌, 鞁犼碃鞛愲姅 雿� 鞚挫儊 VERV 雮措秬鞛愱皜 鞎勲嫏雼堧嫟.

Points cl茅s du Formulaire 4 de Verve Therapeutics (VERV)

Le 25 juillet 2025, la CFO Allison Dorval a d茅clar茅 la cession de toutes les actions restantes de Verve suite 脿 l'acquisition annonc茅e pr茅c茅demment par Eli Lilly. Les transactions cod茅es 芦 U 禄 confirment le traitement automatique selon l'accord de fusion du 16 juin 2025 :

  • 13 280 actions ordinaires remises contre 10,50 $ en esp猫ces plus un CVR par action ; solde d'actions apr猫s transaction : 0.
  • Rachat en esp猫ces de 513 000 options d'achat d'actions (prix d'exercice de 6,01 $ 脿 12,75 $) et 80 625 RSU ; toutes les positions d茅riv茅es sont d茅sormais nulles.

Le d茅p么t pr茅cise les modalit茅s de conversion : paiement en esp猫ces 茅gal 脿 l'茅cart (le cas 茅ch茅ant) et 茅mission d'un CVR non n茅gociable d'une valeur maximale de 3,00 $, conditionn茅 脿 la r茅alisation d'un jalon. La finalisation de l'offre publique d'achat et de la fusion ult茅rieure le 25 juillet 2025 fait de Verve une filiale en propri茅t茅 exclusive de Lilly ; la personne d茅clarant n'est plus un initi茅 de VERV.

Wichtige Erkenntnisse aus dem Form 4 von Verve Therapeutics (VERV)

Am 25. Juli 2025 meldete CFO Allison Dorval die Ver盲u脽erung aller verbleibenden Verve-Aktien infolge der zuvor angek眉ndigten 脺bernahme durch Eli Lilly. Transaktionen mit dem Code 鈥濽鈥� best盲tigen die automatische Abwicklung gem盲脽 dem Fusionsvertrag vom 16. Juni 2025:

  • 13.280 Stammaktien wurden f眉r 10,50 USD in bar plus eine CVR pro Aktie eingereicht; Aktienbestand nach der Transaktion: 0.
  • Auszahlung von 513.000 Aktienoptionen (Aus眉bungspreise 6,01鈥�12,75 USD) und 80.625 RSUs; alle derivativen Positionen sind jetzt auf null.

Die Einreichung erl盲utert die Umwandlungsmodalit盲ten: Barausgleich in H枚he der Differenz (sofern zutreffend) und Ausgabe eines nicht handelbaren CVR im Wert von bis zu 3,00 USD, abh盲ngig von einem Meilenstein. Der Abschluss des 脺bernahmeangebots und der anschlie脽enden Fusion am 25. Juli 2025 macht Verve zu einer hundertprozentigen Tochtergesellschaft von Lilly; die meldende Person ist kein Insider von VERV mehr.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
X
 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
MacLean Michael F
(Last) (First) (Middle)
C/O VERVE THERAPEUTICS, INC.
201 BROOKLINE AVENUE, SUITE 601
(Street)
BOSTON MA 02215
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Verve Therapeutics, Inc. [ VERV ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/25/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $5.02 07/25/2025 D 136,139 (1)(2) (1)(2) Common Stock 136,139 (1)(2) 0 D
Stock Option (right to buy) $5.73 07/25/2025 D 42,200 (1)(2) (1)(2) Common Stock 42,200 (1)(2) 0 D
Explanation of Responses:
1. Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the "Effective Time"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration") (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such
2. (continued from footnote 1) Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting).
/s/ Andrew Ashe, as Attorney-in-Fact for Michael F MacLean 07/28/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

When did Eli Lilly's acquisition of Verve Therapeutics (VERV) close?

The merger became effective on July 25 2025.

How much cash did VERV shareholders receive per share?

Each share was exchanged for $10.50 in cash plus one contingent value right (CVR) worth up to $3.00.

How many shares did CFO Allison Dorval tender?

She disposed of 13,280 common shares.

What happened to the CFO's stock options and RSUs?

513,000 options and 80,625 RSUs were cancelled for cash and CVRs; none remain outstanding.

Does the CFO hold any Verve equity after the merger?

No. The filing shows 0 shares and 0 derivative securities remaining.

What is the potential value of the contingent value right (CVR)?

Each CVR may pay up to $3.00 in cash if a specified milestone is achieved.
Stock VERV logo
Verve Therapeutics, Inc.

NASDAQ:VERV

VERV Rankings

#4349 Ranked by Market Cap
N/A Ranked by Dividends

VERV Latest News

Jul 25, 2025
Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
Jul 24, 2025
Lilly and Verve announce expiration of Verve tender offer
Jun 17, 2025
Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
Jun 2, 2025
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 28, 2025
Verve Therapeutics to Participate in Upcoming Investor Conferences

VERV Latest SEC Filings

Jul 28, 2025
[SCHEDULE 13G/A] Verve Therapeutics, Inc. SEC Filing
Jul 28, 2025
[Form 4] Verve Therapeutics, Inc. Insider Trading Activity
Jul 28, 2025
[Form 4] Verve Therapeutics, Inc. Insider Trading Activity
Jul 28, 2025
[Form 4] Verve Therapeutics, Inc. Insider Trading Activity
Jul 28, 2025
[Form 4] Verve Therapeutics, Inc. Insider Trading Activity

VERV Stock Data

994.04M
84.54M
5.04%
90.12%
16.74%
Biotechnology
Pharmaceutical Preparations
United States
BOSTON